ScreenerHero

CELCCelcuity Inc.

NAS · US · Healthcare · Biotechnology · celcuity.com
93.53USD-0.13%Mkt Cap: 4.58B $P/E: —

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolis…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap4.58B $
Enterprise Value4.43B $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-177.04M $
Revenue/Share—
Last Price93.53 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees155
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1132.13
PEG—
EV/EBITDA-21.26
EV/Revenue—
P/S—
P/B-347.01
EPS (TTM)-4.16
EPS (Forward)-0.08
52W Range
44.4246% of range151.02
52W High151.02 USD
52W Low44.42 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-176.06%
ROA-37.95%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-153.28M $
CapEx (TTM)249.00K $
FCF Margin—
FCF Yield-1.57%
Net Debt340.99K $
Net Debt/EBITDA-0.00
Balance Sheet
Debt/Equity3.20
Current Ratio8.93
Quick Ratio8.68
Book Value/Sh-0.2610 USD
Cash/Share15.41 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)161.09 USD
Upside (mean)+72.2%
Target Range140.00 USD – 177.00 USD
$140.00+72.2% to mean$177.00
# Analysts11
Ownership
Shares Out.48.93M
Float29.72M
Insiders10.07%
Institutions110.34%
Short Interest
Short Ratio5.9d
Short % Float31.62%
Short % Out.21.05%
Shares Short10.26M
Short (prev mo.)10.97M
Technical
SMA 5093.77 (-0.3%)
SMA 200105.46 (-11.3%)
Beta0.20
S&P 52W Chg18.16%
Avg Vol (30d)1.31M
Avg Vol (10d)846.03K
Technical Indicators
RSI (14)51.8
MACD-0.8061
MACD Signal-1.8167
MACD Hist.+1.0106
BB Upper97.20 USD
BB Middle89.07 USD
BB Lower80.93 USD
BB Width18.27%
ATR (14)5.440 USD
Vol Ratio (20d)0.83x